Many clinical trials have shown the effectiveness of anti-PD-1/or anti-PD-L1 immunotherapy, compared to docetaxel, in second-line treatment of NSCLC patients regardless of the PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.